(a) Jamerson KA, Bakris GL, Wun C-C, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez EJ, Weber MA
(b) Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K
(c) Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M
(d) Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ

(a) Rationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial
(b) Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk
(c) Exceptional early blood pressure control rates: The ACCOMPLISH trial
(d) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

(a) Am J Hypertens 2004;17:793–801
(b) Blood Press 2007;16:13–9
(c) Blood Press 2007;16:80–6
(d) N Engl J Med 2008;359:2417–28

Hypertension

To compare the effects of treatment with benazepril plus amlodipine with that of benazepril plus hydrochlorothiazide on cardiovascular mortality and morbidity when used as first-line treatment for hypertension

Randomised, double-blind

Mean 36 months

11,506 patients (5744 benazepril-amlodipine, 5762 benazepril-hydrochlorothiazide), mean age 68.4 ± 6.9 years, with mean BP 145/80 mm Hg and mean body mass index of 31.0 ± 6.2 kg/m²

Benazepril, 40 mg/day, plus amlodipine, 5–10 mg/day, or hydrochlorothiazide, 12.5–25 mg/day

Other antihypertensive medications may be added to achieve target BP < 140/90 mm Hg or < 130/80 mm Hg for patients with diabetes or renal insufficiency

The primary outcome of death from cardiovascular causes, fatal or nonfatal MI, fatal or nonfatal stroke, hospitalisation for angina, resuscitation after sudden cardiac arrest, and coronary revascularisation occurred in 552 patients in the benazepril-amlodipine group compared to 679 patients in the benazepril-hydrochlorothiazide group (9.6% vs 11.8%, relative risk reduction 19.6%, hazard ratio 0.80; p < 0.001)

The trial was terminated early because the boundary of the prespecified stopping rule was exceeded. Data on the progression of chronic kidney disease in both treatment groups have been published in Lancet 2010;375:1173–81